

Claims

1. An allogeneic immunotherapy vaccine for the treatment of prostate cancer in a patient, comprising an adjuvant, cells from a first allogeneic normal prostate cell line, cells from a second allogeneic cell line obtained from a primary prostate cancer biopsy, and cells from a third allogeneic cell line obtained from a metastasis of prostate cancer, wherein the cells of the second allogeneic cell line exhibit tumour associated glycoprotein related to sialylated Tn antigen.
2. A vaccine as described in claim 1, wherein the adjuvant comprises one or more of bacille Calmette-Guérin, a *Mycobacterium*, *Mycobacterium vaccae*, Tetanus toxoid, Diphtheria toxoid, *Bordetella Pertussis*, interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, and Incomplete Freund's Adjuvant.
3. A vaccine as described in claim 1, wherein the adjuvant comprises inactivated *Mycobacterium vaccae* bacilli.
4. A vaccine as described in claim 1, wherein the adjuvant comprises inactivated bacilli Calmette-Guerin.
5. A vaccine as described in claim 1, wherein the third allogeneic cell line is derived from a prostate cancer that has metastasised to one of the lymph nodes, bone, brain and liver.
6. A vaccine as described in claim 5, wherein the first cell line is OnyCap-23, the second cell line is P4E6 and the third cell line is LnCaP.
7. A vaccine as described in claim 5, comprising cells from at least two cell lines derived from prostate cancers that have metastasised to one or more tissues selected from the group consisting of the lymph nodes, bone, brain and liver.
8. A vaccine as described in claim 7, comprising cells from at least five cell lines

derived from prostate cancers that have metastasised to one or more tissues selected from the group consisting of the lymph nodes, bone, brain and liver.

9. A vaccine as described in claim 6, comprising cells from at least 2 cell lines that have been derived from primary prostate cancer biopsies.

10. A vaccine as described in claim 9, comprising cells from at least 2 cell lines that have been derived from primary prostate cancer biopsies.

11. An allogeneic immunotherapy vaccine for the treatment of prostate cancer in a patient, comprising an adjuvant, allogeneic cells from a first normal prostate cell line, allogeneic cells from a second immortalized cell line obtained from a prostate cancer biopsy, and allogeneic cells from a third immortalized line obtained from a prostate cancer biopsy.

12. A vaccine as described in claim 1, wherein the allogeneic cells are lethally irradiated to ensure that the cells are replication incompetent.

13. A vaccine as described in claim 12, wherein the cells are irradiated utilising gamma irradiation at 20-400 Gy.

14. A vaccine as described in claim 1, further comprising a cryoprotectant.

15. A vaccine as described in claim 14, wherein the cryoprotectant comprises at least one of 10-30% v/v aqueous glycerol, 5-20% v/v dimethyl sulphoxide and 5-20% w/v human serum albumin.

16. A method of prophylaxis or treatment of prostate cancer, comprising providing the vaccine of claim 1, and administering the vaccine to a patient in a suitable dosage form.

17. A method of treating a prostate cancer that has metastasised to a tissue selected from the group consisting of bone, lymph node, brain and liver, comprising administering the vaccine of claim 1, wherein the third allogeneic cell line of the vaccine is derived from a

prostate cancer that has metastasised to the selected tissue.

18. An allogeneic immunotherapy vaccine as described in claim 17, wherein the first allogeneic cell line is OnyCap-23.